INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

NCT05438186 · Withdrawn

Last updated 2026-05-28

This study examined how Saxenda®, a weight-loss medication, was used and stopped in real-world medical settings in Turkey by reviewing past patient records of people with obesity.

Status Withdrawn Stopped before any participant enrolled.

Type Observational

Who can join Ages 18+ · all sexes

Timeline Started 2022-09 · est. completion 2022-10

Where 1 site · Turkey (Türkiye)

What this study is testing ClinicalTrials.gov NCT05438186 ↗

Description as written by the study sponsor.

The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according to local clinical practice for weight management, on adult participant's in a real world setting in Turkey. The study will last for about 5 months.

Treatments tested

Liraglutide Drug

Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05438186 ↗